# Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe

> **NCT03091127** · — · COMPLETED · sponsor: **Amgen** · enrollment: 705 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03091127
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-14
- **Primary completion:** 2020-03-17
- **Final completion:** 2020-03-17
- **Target enrollment:** 705 (ACTUAL)
- **Last updated:** 2022-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03091127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03091127, "Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03091127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*